Jon Lieber | U.S. CFO, Entera |
Roger Garceau | Interim CEO |
Dr. Phillip Schwartz | President of R&D |
Arthur Santora | Chief Medical Officer |
Brett Hoffman | Maxim Group |
Good morning and welcome to Entera Bio's Conference Call to discuss the Interim Six Month Results from the EB613 Phase 2 Clinical Trial and the Financial and Operating Results from the Second Quarter of 2020. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to your speaker today Jon Lieber, the U.S. based CFO of Entera.